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Objective. The aim of this study was to compare gestational age at delivery and the performance of mid-
dle cerebral artery (MCA), ductus venosus (DV), and umbilical artery Doppler parameters in the prediction
of perinatal mortality and morbidity in intrauterine growth-restricted (IUGR) fetuses delivered at 32 weeks
or earlier. Methods. The study population consisted of 41 patients with IUGR fetuses. Delivery occurred
for maternal or fetal indications. Two-tailed χ2 and Fisher exact tests, an independent t test, and logis-
tic regression were used for the analysis. P < .05 was considered statistically significant. Results.
Gestational age at delivery ranged between 23.1 and 32 weeks (median, 27.6 weeks). There were 17
perinatal deaths. Ninety-four percent of the perinatal deaths occurred when the fetuses were delivered
before 29 weeks. No fetus survived when delivered before 25 weeks. Two parameters predicted the
perinatal mortality: gestational age at delivery (odds ratio, 0.52; 95% confidence interval, 0.31–0.88)
and the combination of abnormal MCA peak systolic velocity + DV reversed flow (odds ratio, 10.2; 95%
confidence interval, 1.8–57). For each week of pregnancy, there was a reduction in perinatal mortality
of 48%. No Doppler parameters were significantly associated with perinatal morbidity. Conclusions.
Gestational age at delivery and the combination of abnormal MCA peak systolic velocity + DV reversed
flow in very preterm IUGR fetuses were the best parameters in predicting perinatal mortality. The
decreased perinatal mortality that is found for each week IUGR fetuses remain in utero should be taken
into account when a decision to deliver an IUGR fetus before 30 weeks is made. Key words: biophysi-
cal profile; ductus venosus; middle cerebral artery; peak systolic velocity; pulsatility index.
Abbreviations
ARF, absent/reversed flow; CI, confidence interval; DV,
ductus venosus; GA, gestational age; IUGR, intrauterine
growth restriction; MCA, middle cerebral artery; PI, pul-
satility index; PSV, peak systolic velocity; RF, reversed
flow; UA, umbilical artery
ntrauterine growth restriction (IUGR) has been
defined as failure to attain optimal intrauterine
growth. Although scientifically correct, this definition
is difficult to apply in practice because “optimal
growth” cannot be easily determined. The American
College of Obstetricians and Gynecologists has chosen to
define IUGR as a fetus with an estimated weight below
the 10th percentile for gestational age (GA)1 because peri-
natal mortality and morbidity increase when the birth
weight is below that percentile.2–4 With approximately
4 million births per year in the United States, 400,000
neonates will have a birth weight below the 10th per-
centile. Not all IUGR neonates are at risk for adverse out-
come; some are constitutionally small but otherwise
healthy neonates.5
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Although several factors are implicated in the
origin of IUGR, it has been suggested that the most
important role appears to be played by placental
insufficiency.6–8 Placental insufficiency causes
increased placental vascular resistance, and it can
be assessed by Doppler ultrasonography of the
umbilical artery (UA).7,8
Intrauterine growth restriction secondary to
placental insufficiency is a major cause of peri-
natal morbidity and mortality in the United
States.9 Once IUGR is identified, obstetric man-
agement is focused on ensuring safety while the
fetus continues to mature within a potentially
hostile intrauterine environment. In the United
States, the standard of care for management and
delivery of the IUGR fetus at less than 32 weeks is
based on serial biophysical profile evaluations or
cardiotocography,10 whereas in Europe, it is
based on the results of cardiotocography.11,12
Recently, it has been suggested that in IUGR
fetuses, abnormal ductus venosus (DV) Doppler
parameters are excellent predictors of adverse
perinatal outcome.11–15 A parameter that has not
been well investigated in IUGR fetuses is the
middle cerebral artery (MCA) peak systolic veloc-
ity (PSV). One pilot study reported that the MCA
PSV is increased in IUGR fetuses.16 More recent-
ly, we have reported that the MCA PSV predicts
perinatal mortality better than the MCA pulsatil-
ity index (PI).17 This may be due to better correla-
tion of blood velocity with blood flow compared
with the PI (K. Clarke, PhD, oral communication,
2004).
The aim of this study was to compare GA at
delivery and the performance of UA, MCA, and
DV Doppler parameters in the prediction of peri-
natal mortality and morbidity in preterm severe
IUGR fetuses.
Materials and Methods
Clinical Procedures
This was a retrospective study. The patients includ-
ed in this study were either involved in research
protocols approved by the Human Investigation
Committee or part of a database on IUGR fetuses,
and their inclusion for this study was approved by
the Human Investigation Committee.
Among fetuses with an estimated weight below
the third percentile and a UA PI below the 95%
confidence interval (CI),18 we selected those
without structural anomalies, delivered at 32
weeks’ gestation or earlier, for whom Doppler
measurements of the DV and MCA were obtained.
The presence of absent/reversed flow (ARF) for
the DV as well as the UA was also determined.
Gestational age at delivery was based on certain
last menstrual period or second-trimester ultra-
sonographic dating. Delivery was indicated in the
presence of nonreassuring fetal testing, fetal
death, or worsening maternal or fetal conditions
as determined by the managing physician.
Nonreassuring fetal testing was defined by the
presence of either continuous variable/late
decelerations or a biophysical profile of 4 or less.
When delivery was indicated and the fetus was
less than 500 g, the patient was counseled on the
poor prognosis and offered the option of nonin-
tervention. Steroids were administered to all
pregnant patients when fetuses were considered
viable. Fetuses with abnormal karyotypes or sus-
picion of infection were not included in the
study. Fetal weights were calculated and evaluat-
ed according to the nomograms established by
Hadlock and coworkers.19
Pulsed wave Doppler ultrasonographic studies
were performed with 1 of 4 color Doppler sys-
tems (Sequoia, Siemens Medical Solutions,
Mountain View, CA; Voluson 530 and 730 Expert,
GE Healthcare, Milwaukee, WI; and HDI 5000,
Philips Medical Systems, Bothell, WA) using 3.5-
or 5-MHz probes. All recordings were obtained
in the absence of fetal breathing and fetal move-
ments. For each vessel, an average of 3 consecu-
tive Doppler velocity waveforms was used for
statistical analysis. A free loop of the UA was
sampled, and the PI was used to analyze the
waveforms. The MCA was studied as reported
previously,20 maintaining as close as possible to
0° for the angle of insonation. The MCA wave-
forms were quantified by using the PI as well as
the PSV. The DV was sampled soon after its origin
from the umbilical vein.
The MCA PI was considered abnormal if the
measurements were below the lower limit of nor-
mal reported previously20; the MCA PSV was con-
sidered abnormal if the measurements were
above the upper limit of normal established
previously.21 A UA PI above the 95% CI for GA of
our reference range was considered abnormal.
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Absent or reversed end-diastolic velocity in the
UA was also considered abnormal. For the DV,
different patterns, abnormal DV PI22 and ARF
in coincidence with atrial contraction, were
considered independently as 2 different pat-
terns of progressive severity. We also consid-
ered the combination of abnormal MCA PSV +
DV reversed flow (RF).
Perinatal mortality was defined as fetal mortal-
ity occurring between 20 weeks’ gestation and
28 days after birth. Major neonatal complica-
tions included grade III or IV intracerebral hem-
orrhage according to the classification of Papile
et al23 and bronchopulmonary dysplasia.
Statistical Analysis
We evaluated the Doppler parameters (UA PI, UA
ARF, UA RF, MCA PSV, MCA PI, DV PI, DV ARF, DV
RF, and the combination abnormal MCA PSV +
DV RF) and the GA at delivery against the perina-
tal outcome. When a fetus had serial measure-
ments performed, the last measurement before
delivery was considered for the analysis.
The Doppler parameters were analyzed as cat-
egorical variables. The χ2 and Fisher exact tests
were used for categorical variables. The signifi-
cant parameters were further analyzed by a for-
ward stepwise logistic regression analysis. In
this analysis, we also included the GA. A t test
for independent groups was used to compare
whether there was a difference in GA at delivery
between the neonates who survived and those
who died either in utero or within the first 4
weeks of life. P < .05 was considered to indicate
statistical significance. Statistical analysis was
performed with SPSS version 14.0 statistical soft-
ware for Windows (SPSS Inc, Chicago, IL). 
Results
Among the 41 fetuses who met the inclusion cri-
teria, GA at delivery ranged between 23.1 and 32
weeks (median, 27.6 weeks). Twenty-nine fetuses
were studied within 24 hours of delivery. The
other 12 fetuses were studied within 72 hours of
delivery. Characteristics and perinatal outcomes
of the study population are reported in Table 1.
Twenty-four women had no illnesses before the
pregnancy. Where maternal illnesses before
pregnancy existed, problems included chronic
hypertension (n = 15), asthma (n = 1), and
hyperthyroidism (n = 1). Indications for delivery
were nonreassuring fetal testing (n = 21), severe
preeclampsia (n = 8), HELLP (hemolytic anemia,
elevated liver enzymes, low platelet count) syn-
drome (n = 5), and intrauterine fetal death (n = 7).
All fetuses except those who died in utero were
born by cesarean delivery.
The univariate analyses indicated that the fol-
lowing parameters were significantly associated
with perinatal mortality: UA RF, abnormal MCA
PSV, DV RF, and the combination of abnormal
MCA PSV + DV RF (Table 2). When these param-
eters were entered in the logistic regression, it
was found that 2 parameters predicted perinatal
mortality: GA at delivery and the combination
abnormal MCA PSV and DV RF (Nagerlke R2 = 55;
Table 3). Fetuses who died were at a significantly
lower GA at the time of delivery than those who
survived (P < .05). For each additional week the
fetuses remained in utero, perinatal mortality
decreased by 48%. One assumption that our
study makes is that there is a linear relationship
between GA at delivery and mortality. Although
this might not be the case for all gestations, the
relationship between these 2 variables can be
considered linear to a first approximation at
early GAs (eg, between 25 and 29 weeks).
Among the fetuses who survived, none had
grade III or IV intraventricular hemorrhage.
Bronchopulmonary dysplasia developed in 14
fetuses. No Doppler parameters were signifi-
cantly associated with bronchopulmonary
dysplasia.
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Table 1. Characteristics of the Study Population (N = 41)
Characteristic Median (Range)
GA at Doppler study, wk 27.6 (23–32)
Interval between last scan and delivery, d 1 (0–3)
GA at delivery, wk
Total population 27.6 (23.1–32)
Perinatal deaths (n = 17) 26.6 (23.1–30.3)
Intrauterine fetal deaths (n = 7) 26 (23.1–28.6)
Neonatal deaths (n = 10) 26.8 (24.6–30.3)
Survivors (n = 24) 29 (25.2–32)
Birth weight, g
Total population 550 (282–1240)
Perinatal deaths (n = 17) 471 (282–680)
Intrauterine fetal deaths (n = 7) 440 (282–680)
Neonatal deaths (n = 10) 490 (300–660)
Survivors (n = 24) 685 (360–1240)
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Discussion
Our study showed that the GA at delivery and the
combination of abnormal MCA PSV + DV RF
were the best predictors of perinatal mortality in
IUGR fetuses delivered earlier than 32 weeks. Our
data also showed that there was a 48% reduction
in the incidence of perinatal mortality for every
additional week of gestation at delivery. Although
we included fetuses with an estimated fetal
weight below the third percentile, we believe that
out data can be applied to fetuses with an esti-
mated weight below the 10th percentile who
have abnormal UA Doppler parameters.
Previous studies have emphasized the appear-
ance of a temporal sequence of Doppler and bio-
physical changes that precede the peripheral and
central circulatory system changes of the severe-
ly growth-restricted fetus.11–13 It has been sug-
gested that an abnormal DV has the potential to
become a key factor in the management and
optimum timing for delivering the IUGR fetus.
Indeed, some investigators perform a cesarean
delivery simply on the basis of the deterioration
of the DV Doppler waveforms.24
Although the blood flow changes seen in the DV
are important predictors of a poor outcome, the
mechanisms to determine the optimal timing of
IUGR fetus delivery before 32 weeks remain con-
troversial. It would be very important to deter-
mine whether delivery of the IUGR fetus at less
than 32 weeks should be based only on changes
in the DV with identification of ARF in this vessel
or whether delivery should be based rather on
other testing parameters. The overwhelming
impact of GA on survival suggests that addition-
al information about the IUGR fetus at less than
32 weeks might potentially allow us to delay
delivery in selected cases and improve the out-
come. Therefore, further evaluation of addition-
al measurements, including the MCA PSV, and
acknowledgment of various methods of fetal
testing, including cardiotocography and bio-
physical profile changes, are crucial to under-
standing how to optimize obstetric care in this
high-risk population.
We have previously determined that the MCA
PSV increased after the decreased MCA PI and
remained above its normal reference range up to
a few hours before a fetal death or nonreassuring
fetal testing occurred.17 We believe that it is not
necessary to assess the MCA PSV and DV in IUGR
fetuses if there is forward diastolic flow in the UA.
This initial and qualitative analysis of the UA
(present versus absent end-diastolic velocity)
could be performed by most sonographers.
When the UA end-diastolic velocity is absent, the
fetus could be referred for more sophisticated
tests at appropriate centers.
In our study, 94% (16/17) of the perinatal mor-
tality occurred when the fetuses were delivered
before 29 weeks. No fetus survived when deliv-
ered at a GA earlier than 25 weeks. It must be
emphasized that IUGR fetuses who are detected
early in the third trimester have a significant
decrease in perinatal mortality for each week
that they remain in utero; this should be taken
into account when a decision to deliver an IUGR
fetus before 30 weeks is made.
Some weaknesses of our study included the fact
that the study was not longitudinal; therefore, we
were not able to determine when serial changes
occurred in both the MCA PSV and DV blood
velocity. The IUGR group reported here repre-
sented a heterogeneous group because maternal
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Table 2. Unadjusted Odds Ratios for Doppler Parameters Selected
by the Univariate Analysis to Predict Perinatal Mortality (N = 41)
95% CI
Parameter OR Lower Upper P
MCA PI 0.3 0.07 1.2 .15
UA ARF 0.8 0.6 1.0 .06
DV PI 2.8 0.8 10.5 .2
DV RF 9.1 2.1 38.3 .003
MCA PSV 11.4 1.3 101 .01
MCA PSV + DV RF 12 2.7 53.6 .001
UA RF 13.5 1.5 119 .006
OR indicates odds ratio.
Table 3. Parameters Selected by the Forward Stepwise Logistic
Regression Analysis as Best Predictors of Perinatal Mortality in 41
IUGR Fetuses
95% CI
Parameter OR Lower Upper P
MCA PSV + DV RF 10.2 1.8             57 .008
GA at delivery 0.52 0.31           0.88 .01
OR indicates odds ratio.
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conditions present before pregnancy and those
occurring during pregnancy influenced the time
of delivery in many of our fetuses. Moreover, the
small number of patients may have limited the
ability of individual Doppler parameters to pre-
dict perinatal morbidity.
A longitudinal study of DV and MCA PSV that
includes a larger number of fetuses, considers
long-term outcome, and also differentiates
between idiopathic IUGR fetuses on the one
hand and IUGR fetuses associated with known
causes of placental insufficiency on the other is
warranted at this time. 
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